Bullous Drug Reaction with Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- 1*,
- 2
- 1Department of Dermatology, All India Institutes of Medical Sciences (AIIMS) Raebareli, Raebareli, Uttar Pradesh, India.
- 2Department of Pharmacology, All India Institutes of Medical Sciences (AIIMS) Raebareli, Raebareli, Uttar Pradesh, India.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: K. Geetha
Department of Dermatology, All India Institutes of Medical Sciences (AIIMS) Raebareli, Raebareli, Uttar Pradesh, India.
Email: geetharbl@outlook.com
Copyright: © 2022 The Author(s). This is an open access article.
Published: Jan 1, 2022, Received: Dec 20, 2021, Accepted: Feb 12, 2022
Abstract
Hypoglycemic drugs in the dipeptidyl peptidase-4 (DPP-4) inhibitor class are used as a second-line treatment for type 2 diabetes mellitus. With DPP-4 inhibitors, there have been a few reports of cutaneous side effects such as bullous response, fixed drug eruption, and photosensitivity. There is no definitive pathophysiology for the above mentioned allergic reactions. Sitagliptin phosphate belongs to the DPP-4 inhibitor class. This is a case report of a sitagliptin-induced bullous drug reaction manifesting three weeks after starting therapy. He had bullous pemphigoid-like eruptions all over the body. The patient showed improvement once sitagliptin was discontinued alon with oral and topical steroid treatment.
Keywords
Subject
Readers Also Viewed
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Knowledge, Attitude, and Practice on Digital Eye Strain Among Healthcare Students at a Private University in Northern Peninsular Malaysia
Lim Chin Hung, Subramani Parasuraman, Sam Aaseer Thamby
Jan 1, 2026